<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "magnesium sulfate inj VIAL">
<dose><value>1000</value>
<value>4000</value>
<value>2000</value>
<value>4</value>
<value>1</value>
<value>2</value>
<value>0.5 - 1</value>
<value>2 - 5</value>
<value>1 - 2.5</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>magnesium sulfate inj VIAL</value>
</drugname><strength><value>200 mg/mL</value>
<value>500 mg/mL</value>
</strength><frequency><value>ONCE</value>
<value>CONTINUOUS</value>
</frequency><instruction><value>DAY 1 of 21. Administer dose diluted in 250 mL 0.9% sodium chloride as prehydration over 30 minutes.</value>
<value>DAY 2 of 21. Administer dose diluted in 250 mL 0.9% sodium chloride as prehydration over 30 minutes.</value>
<value>DAY 3 of 21. Administer dose diluted in 250 mL 0.9% sodium chloride as prehydration over 30 minutes.</value>
<value>DAY 1 of 21. Administer dose diluted in 1000 mL 0.9% sodium chloride as prehydration over 2 hours.</value>
<value>DAY 1 of 28. Administer dose diluted in 1000 mL 0.9% sodium chloride as prehydration over 2 hours.</value>
<value>DAY 8 of 28. Administer dose diluted in 1000 mL 0.9% sodium chloride as prehydration over 2 hours.</value>
<value>DAY 1 of 21. Administer dose diluted in 500 mL 0.9% sodium chloride over 1 hour prior to CISplatin. (Prehydration)</value>
<value>Administer over 20 minutes for management of pregnancy induced hypertension or premature labor.</value>
<value>Administer by direct injection over 1 minute.</value>
<value>Administer by direct injection over 2 minutes.</value>
<value>Administer over 15 minutes.</value>
<value>Administer by continuous infusion for up to 24 hours. </value>
<value>Administer by continuous infusion.</value>
<value>Administer over 5 hours</value>
<value>Administer over 30 minutes. </value>
<value>Administer by continuous infusion until delivery or a maximum of 24 hours.</value>
<value>DAY 1. Administer dose diluted in 1000 mL 0.9% sodium chloride posthydration over 2 hours.</value>
<value>DAY 8. Administer dose diluted in 1000 mL 0.9% sodium chloride posthydration over 2 hours.</value>
<value>DAY 1 of 21. Administer dose diluted in 1000 mL 0.9% sodium chloride posthydration over 2 hours.</value>
<value>DAY 1 of 21. Administer dose diluted in 1000 mL 0.9% sodium chloride at a rate less than or equal to 50 mg/minute.</value>
</instruction><volume><value>10 mL</value>
<value>2 mL</value>
<value>50 mL</value>
</volume><units><value>mg</value>
<value>g</value>
<value>g/hour</value>
<value>g/hr</value>
</units><additionalnotes><value>Requirement  determined by physician.</value>
<value>To control persisten ventricular fibrillation/Pulseless ventricular tachycardia associated with hypomagnesemia.</value>
<value>AMI/Torsades de Pointes. Loading dose.</value>
<value>AMI. Follow-up dose.</value>
<value>Torsades de Pointes. Follow-up dose.</value>
<value>Severe hypomagnesemia</value>
<value>Pregnancy induced hypertension</value>
<value>Antenatal Neuroprotection of preterm infant</value>
<value>May be used as alternative to 1000 mL 0.9% sodium chloride posthydration.</value>
<value>May be used as alternative to 1000 mL 0.9% sodium chloride.</value>
<value>May be used as alternative to 1000 mL 0.9% sodium chloride prehydration.</value>
</additionalnotes><population><value>CISplatin/etoposide (IV). Small Cell Lung Cancer.</value>
<value>Pemetrexed / CISplatin. Mesothelioma.</value>
<value>Etoposide (Days 1-5)/CISplatin (Days 1 &amp; 8) with concurrent RT. Pancoast Tumor</value>
<value>DOXOrubicin/CISplatin/cyclophosphamide (PAC). Thymic Malignancy</value>
<value>CISplatin/DOXOrubicin/vinCRIStine/cyclophosphamide. Thymoma</value>
<value>Adjuvant Vinorelbine/CISplatin (every 28 days). Non-Small Cell Lung Cancer</value>
<value>Adjuvant Vinorelbine/CISplatin (every 21 days). Non-Small Cell Lung Cancer</value>
<value>Pemetrexed/CISplatin. Non-Small Cell Lung Cancer</value>
<value>Vinorelbine / CISplatin. Advanced NSCLC</value>
<value>CISplatin &amp; Vinorelbine with CONCURRENT RT. Non-Small Cell Lung Cancer</value>
<value>Gemcitabine / CISplatin. Non-Small Cell Lung Cancer</value>
<value>CISplatin/etoposide (po). Small Cell Lung Cancer</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3090</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3006</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3089</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary.</value>
<value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Anticonvulsants, Anticonvulsants, Miscellaneous</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>00392618</value>
<value>02139499</value>
<value>00602264</value>
</din></drug>